Anemia – Talk Bio

AstraZeneca Acquires FibroGen’s China Unit for $160 Million, Gaining Full Control of Anemia Drug Roxadustat

2 months ago talkbio0Tagged Acquisition, Anemia, AstraZeneca, China, Chronic Kidney Diseases, Drug Industry, FibroGen, roxadustat

AstraZeneca, FibroGen, China, acquisition, roxadustat, anemia, chronic kidney disease, pharmaceutical industry

FibroGen Lays Off 75% of US Staff After Cancer Drug Fails in Two Phase III Trials

9 months ago talkbio0Tagged Anemia, Antineoplastic Agents, Astellas, AstraZeneca, FibroGen, Neoplasms, pamrevlumab, Pancreatic carcinoma, Pharmacotherapy, Phase 3 Clinical Trials, roxadustat

FibroGen, cancer drug, layoffs, Phase III trials, pamrevlumab, oncology, pancreatic cancer, chemotherapy, anaemia therapy, roxadustat, Astellas, AstraZeneca

FDA Approves Vadadustat (Vafseo) for Anemia in Chronic Kidney Disease Patients on Dialysis and Daprodustat (Jesduvroq) for Dialysis-Dependent CKD Adults

1 year ago talkbio0Tagged Anemia, Approved, Black Box Warning, Chronic Kidney Diseases, Daprodustat, Effectiveness, Hemoglobin concentration result, Jesduvroq, Oral Medication, post-marketing safety, Safety, United States Food and Drug Administration, vadadustat, Vafseo

Anemia, Chronic Kidney Disease (CKD), Vadadustat (Vafseo), Daprodustat (Jesduvroq), Oral medication, FDA approval, Hemoglobin levels, Black Box Warning, Efficacy and safety data, Post-marketing safety data